Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
What Comes After Fulvestrant? A Real World Multicenter Retrospective Study-Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients in China.
There is no evidence of treatment after progression of Ful. We retrospectively evaluated HR+, HER2- MBC patients failed on Ful 500mg as first line or second line therapy from 2014 to 2017 in 6 institutions. Treatment pattern, PFS, OS and safety were analyzed to figure out the situation and efficacy of treatment after Fulvestrant.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Endocrine therapy | use endocrine therapy (ET) after Fulvestrant, include but not limited to: tamoxifen, anastrozole, letrozole, exemestane, exemestane + everolimus | ||
| Chemotherapy | use Chemotherapy (CT) after Fulvestrant, include but not limited to: capecitabine, docetaxel-based, vinorelbine, paclitaxel-based |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| PFS | Progression free survival | 6 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| OS | Overall survival | From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months |
| Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 |
| Measure | Description | Time Frame |
|---|---|---|
| Fulvestrant sensitivity | Time cutoff of Fulvestrant PFS related to next line ET or CT efficacy | 6 weeks |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients diagnosed with breast cancer (according to ICD-10) with confirmed metastasis, regardless of being de novo diagnosed or progressed from a non-metastatic stage
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Biyun Wang, Professor | Fudan University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fudan University Shanghai Cancer Center | Shanghai | Shanghai Municipality | 200032 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| D018450 | Disease Progression |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| 6 weeks |
| D017437 |
| Skin and Connective Tissue Diseases |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |